Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Download White Paper
IT in
Healthcare,
Patient
Monitoring &
Telemedicine

Download White Paper

 
Download SlideShare
20
Hot
Stats on
Healthcare
IT

Download SlideShare

 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Paget's: market research reports

1594
Paget's disease of the bone (other terms are Paget's disease, osteitis deformans, osteodystrophia deformans) is a chronic disorder that typically results in inflated and unshaped bone. The condition is named after Sir James Paget, the British surgeon who first described it in the 19th century. The excessive breakdown and formation of bone tissue that occurs with Paget's disease can cause bone to soften, the result being pain, arthritis, deformities, and fractures.

Paget's disease is not often diagnosed in people less than 40 years of age. Women are more commonly affected than men. Prevalence of Paget's disease ranges from 1.5 to 8.0 percent, depending on age and country of residence. Prevalance of familial Paget's disease (where more than one family member has the disease) ranges from 10 to 40 percent in different parts of the world. Because early diagnosis and treatment is important, after age 40, siblings and children of someone with Paget's disease may wish to have an alkaline phosphatase blood test every two or three years. If the alkaline phosphatase level is abnormal, other tests such as a bone-specific alkaline phosphatase test, bone scan, or X-ray can be performed.

RSS Feeds

Paget's market research reports and industry analysis

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar
6/12/2012 | published by: GBI Research
... has released its latest research, “Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar”, which provides insights ...  |  read more...
$3,500.00
Paget's Disease Therapy Area Pipeline Report
3/14/2011 | published by: Life Science Analytics (LSA)
... as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, ...  |  read more...
$1,495.00
Paget's Disease Therapy Pipeline Report
1/6/2011 | published by: Life Science Analytics (LSA)
... drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user ...  |  read more...
$1,495.00
Musculo-Skeletal-Disorders Paget's Disease Therapy Area Pipeline Report
1/7/2010 | published by: Life Science Analytics (LSA)
... as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, ...  |  read more...
$1,495.00